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Syntheses and Cellular Investigations of Di(aspartate) and
Aspartate-lysine Chlorin e6 Conjugates
R. G. Waruna Jinadasa, Zehua Zhou, M. Graça H. Vicente, and Kevin M. Smith*
Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, USA

Abstract
Author Manuscript

Chlorin e6 is a tricarboxylic acid degradation product of chlorophyll a. Four chlorin e6 bis(amino
acid) conjugates were regioselectively synthesized bearing two aspartate conjugates in the
131,173- and 152,173-positions, or at the 131,152 via an ethylene diamine linker. One additional
conjugate bearing two different amino acids, lysine at 131 via an ethylene diamine linker and an
aspartate at 152 via a β-alanine linker was also synthesized. The cytotoxicity and uptake of four
di(amino acid) chlorin e6 conjugates were investigated in human HEp2 cells, and compared with
chlorin e6. The most cytotoxic and most taken up conjugates were the zwitterionic 131,152disubstituted conjugates 28 and 33; these also localized in multiple organelles. In contrast, the
tetra-anionic 131,173- and 152,173-di-aspartyl chlorin e6 conjugates 12 and 13 showed low dark
cytoxicity and lower phototoxicity compared with chlorin e6.
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Graphical Abstract

Regioselective syntheses of chlorin e6 bis(amino acid) conjugates bearing aspartates in the
131,173-, 152,173- and 131,152-positions, and their cell studies are reported.
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Introduction
Photodynamic therapy (PDT) is a special form of cancer photochemotherapy involving a
photosensitizer and light. Selective uptake of a photosensitizer into tumor cells followed by
irradiation with laser light within the “therapeutic window” (λmax 600-800 nm) produces
singlet oxygen and other reactive oxygen species (ROS).1-5 Singlet oxygen, in particular,
readily reacts with nearby local biomolecules (unsaturated lipids, amino acids and DNA) to
*
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cause destruction of apparatus within the cell. Because of limited diffusion of singlet oxygen
through tissue, the destructive PDT effects are mainly localized to the photosensitizercontaining cells, thus minimizing the possibility of damage to normal cells near the tumor.
Two essentials for the success of PDT treatment are: (i) the tumor-targeting ability of the
photosensitizer, and (ii) the wavelength of the light required to activate the photosensitizing
drug. Researchers aim for minimal “dark” toxicity, a high quantum yield of triplet state
formation upon excitation, high selectivity for tumor cells compared with normal cells,
reasonably rapid clearance from normal tissues, and a strong absorption peak between 600
and 800 nm to facilitate maximum light penetration through tumor and normal tissues.

Author Manuscript
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Photofrin is a porphyrin-based photosensitizer mixture that was developed and approved in
several countries for the PDT of melanoma, lung, digestive tract, genitourinary tract and for
treatment of Barrett’s esophagus.3-6 It suffers from the fact that it is ineffective at
wavelengths above 630 nm, and that it clears from tissues so slowly that patients can suffer
from residual skin photosensitivity for weeks after treatment. Thus, a number of so-called
second generation tetrapyrrole photosensitizers have been invented, these usually possessing
strong red-shifted absorption maxima at the red end of the therapeutic window. Examples
are tetra(meta-hydroxyphenyl)chlorin, (mTHPC or Temoporfin), 2-(1-hexyloxyethyl)-2devinyl-pyropheophorbide a (HPPH or Photochlor), mono-L-aspartylchlorin e6 (LS-11, or
Talaporfin) and a phthalocyanine called “Pc4”.3-6 Of these, chlorins (dihydroporphyrins)
have received special attention for PDT because of their intense absorptions above 640 nm.
Indeed, chlorophyll a derivatives are amphiphilic tetrapyrroles that have been extensively
investigated and shown to exhibit low dark toxicities while at the same time able to generate
cytotoxic ROS upon irradiation with light.7-9 Both HPPH and Talaporfin are in advancedstage clinical trials for oncologic PDT treatment;10-13 they exhibit superior PDT activity, and
are rapidly cleared from tissue such that residual photosensitivity in patients is minimized
compared with Photofrin.

Author Manuscript
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Chlorin e6 (1) is a particularly interesting chlorophyll a derivative because it possesses no
less than three chemically different carboxylic acid functions (that could potentially be
differentially functionalized with biomolecules): a nuclear aromatic acid in position 131, a
nuclear acetic acid in position 152, and a propionic side-chain acid that is truly aliphatic, in
position 173. Conjugations of peptides, sugars, lipoproteins, polyethylene glycols, and
polyamines with chlorin e6 have been reported.14-22 Amino acid conjugations, in particular,
have been shown to improve the PDT effects of tetrapyrrole compounds, and the type and
position on the macrocyclic core can have a major impact upon efficacy in PDT. Talaporfin
Org Biomol Chem. Author manuscript; available in PMC 2017 January 21.
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(2) was originally formulated in 1987 as the 173-aspartyl derivative (3) of chlorin e6. Gomi
et al.23 used spectroscopic techniques (mostly) to propose that Talaporfin was in fact (2), not
(3), but this work was almost universally ignored until our own group confirmed by total
synthesis of the three possible isomers (2-4) (and comparison with authentic material), that
(2) was indeed the correct structure for Talaporfin.24 A definitive X-ray structure of the
tetramethyl ester (5) of Talaporfin finally ended all conjecture.24 It was proposed that the
anhydride (6) is an intermediate in the formation of (2) whereby the aspartic acid is not
involved in the first step of the reaction. The anhydride (6) is formed by dehydration using
only DCC or EDC, and then the aspartic acid nucleophile opens the anhydride ring by
attacking the more electrophilic aliphatic carbonyl at position 152.24 This point of view was
solidified by isolation of the anhydride, a single crystal X-ray structure of the anhydride
methyl ester (7), and the demonstration that ring-opening of the anhydride with eight
different nucleophiles resulted only in formation of the 152-conjugate (8).25 Bis-conjugation
was shown to be possible (at 173 and 152) in one case,25 or when two equivalents of DCC or
EDC were used,26 but at no time was the 173-conjugate the sole product of the conjugation.

Author Manuscript

Making use of the differential conjugation methods developed in our earlier work,24
regioselective amino acid conjugates at the 173, 152 and 131 positions of chlorin e6 were
synthesized27 to evaluate the effect in vitro of the conjugation site and structure of the amino
acid on the PDT efficacy of the conjugates, using human carcinoma HEp2 cells. Syntheses
of the 173 and 131 aspartyl regioisomers of mono-L-aspartylchlorin e6 were developed,
along with the corresponding cationic lysine derivatives (which would be expected to show
strong interactions with anionic biomolecules and membranes, resulting in enhanced PDT
effectiveness.28 In addition, molecules with an ethylene diamine or β-alanine spacer group
between the macrocycle and the amino acid were also synthesized. Based on in vitro
biological evaluations, it was concluded that the site of amino acid conjugation, rather than
the nature of the amino acid conjugated, was the major determinant of phototoxicity.27 The
most phototoxic compounds were found to be the 131-regioisomers, bearing either an
aspartic acid or a lysine residue directly conjugated to position 13 of the chlorin macrocycle,
or connected via a β-alanine or ethylene diamine spacer. The most phototoxic compound of
this series, and the most promising for PDT applications, was 131-aspartylchlorin e6.
Unfortunately, poor solubility of these molecules was one of the major drawbacks in the
cellular studies, and some of the sensitizer molecules tended to self-aggregate easily,
resulting in lower cell uptake. In the present work, in order to overcome these shortcomings,
we report the syntheses and biological evaluations of a new series of chlorin e6 derivatives
that possess two amino acids in a single chlorin e6 molecule (Figure 1).

Author Manuscript

Kimani et al.19 recently reported the synthesis of mono-, di- and tri-PEGylated chorin e6
photosensitizers with tri(ethylene glycol) attached at the three carboxylic acid positions in
chlorin e6.19 These were tested for solubility and hydrolytic stability, as well as
phototoxicity, cell uptake and localization in ovarian OVCAR-5 cancer cells. Their results
showed that increasing the number of PEG groups increased the water solubility and cellular
uptake of the compounds. Computational studies also indicated that the PEG groups prevent
formation of aggregates by π-π stacking, by wrapping onto the chlorin ring. Most
significantly an increased number of PEG groups increased the phototoxicity, and cellular
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uptake. We therefore anticipated that an increase in the overall charge of the molecule and
resulting amphiphilicity, might increase the water solubility29,30 and concomitantly decrease
the self-aggregation in biological media.31 Our hypothesis was that a higher number of
charged substituents would increase both the phototoxicity and the cellular uptake. To test
this hypothesis all three possible regioisomers of diamino acid chlorin e6 derivatives were
synthesized (Figure 1). It was found from our previous study, that the position of the amino
acid plays a vital role in determining the conformation of the molecule.27 Therefore new
synthetic routes were developed to prepare all three regioisomers. Both the 152,173- and
131,173-di(amino acid) derivatives were synthesized starting from chlorin e6 (1) and the
131,152-diamino derivatives were synthesized from pheophytin a. Thus, the aims of the
present work were to determine: (i) the degree to which di-(amino acid)-chlorin e6
derivatives were taken up and localized in cancer cells, (ii) the main site(s) of intracellular
accumulation, and (iii) whether the position and charge of the amino acid substituents
influences the dark and photo-toxicity.

Results and Discussion
Synthesis of 152,173-diaspartylchlorin e6 derivative
A major side product in the synthesis of 152-mono-aspartylchlorin e6 derivative (2) was the
152,173-diaspartylchlorin e6 derivative 8,26 the yield of which can be increased by increasing
the number of equivalents of coupling reagent and aspartic acid. According to our proposed
mechanism,24 DCC and DMAP activated the acetic side chain in 1 and formed the
anhydride intermediate 6. The excess coupling reagent can further activate the propionic
acid side chain to form the O-acylisourea anhydride intermediate 9 (Scheme 1).25

Author Manuscript

Thereafter, the free amine group of the amino acid can attack both carbonyl groups in
intermediate 9, one in the anhydride ring and the other one in the O-acylisourea group.
Mechanistic studies revealed the nucleophile first attacks the more reactive 152 position of
the anhydride ring instead of the 131 position, regardless of the size or nucleophilicity of the
molecule. Then the second equivalent can react with the O-acylisourea group to form
diaspartylchlorin e6 derivative 8.

Author Manuscript

The detailed synthetic route to 152,173-diaspartylchlorin e6 methyl ester (12) is shown in
Scheme 2. It was possible to obtain diaspartyl methyl ester 11 in 33% overall yield from
chlorin e6 (1). The optimal yield of diaspartyl chlorin e6 12 (26%) was obtained upon
activation of chlorin e6 with three equivalents of DCC and DMAP in CH2Cl2 at room
temperature for two hours followed by coupling with 2.5 equivalents of di-tert-butyl
protected aspartic acid for 24 hours. Less than three equivalents of DCC and aspartic acid
tended to form significant amounts of the 152-monoaspartic acid conjugate as a side product.
When the number of equivalents of either DCC or aspartic acid was increased, the yield of
diaspartyl chlorin e6 10 improved, but it was not possible to prevent the formation of monoaspartyl conjugate as a side product. Longer reaction times also helped to increase the yield
of diaspartyl derivative 10. After confirming the formation of tert-butyl protected diaspartyl
chorin e6 10 by TLC and mass spectrometry, freshly prepared diazomethane gas was
bubbled through the mixture for five minutes to convert the remaining free acid groups into

Org Biomol Chem. Author manuscript; available in PMC 2017 January 21.
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methyl esters. This reaction was monitored by TLC. It was possible to see two new spots in
the TLC plate. A brighter spot with lower RF value belonged to the desired product 152,173diaspartylchlorin e6 11 and the second spot had a higher RF value similar to that of 152monoaspartlychlorin e6 methyl ester. Purification was achieved via silica gel column
chromatography and the identity of the esterified product 11 was confirmed using 1H NMR
and mass spectrometry. 1H NMR spectroscopy showed four singlets between 3.0 and 4.5
ppm each integrating to three protons. Of the four peaks, three belong to the methyl groups
directly connected to the macrocycle and the remaining peak belongs to the 131 methyl ester
group. The most downfield singlet at δ 4.25 confirmed the formation of the 131 methyl ester
because this peak is unique to the methyl group on the formic (13-) side chain of the
trimethyl ester of chlorin e6 (1). This observation confirmed that aspartic acid coupled with
the acetic (15-) and propionic (17-) side chains of the molecule.

Author Manuscript

In the final step, all four tert-butyl esters in molecule 11 were removed to give 12 in a
TFA/CH2Cl2 mixture for six hours at room temperature. TFA and CH2Cl2 were first
removed and the product was freeze-dried by dissolving it in a water/acetonitrile mixture.
Once the sample was neutralized the color changed from purple to dark green. The identity
of product 12 was confirmed by 1H NMR, 13C NMR and mass spectrometry.
Synthesis of 131,173-diaspartylchlorin e6 derivative

Author Manuscript

There are two possible routes to synthesize the 131,173-chlorin e6 conjugate 13: 1) coupling
of the first amino acid to the propionic acid chain of pheophorbide a (14) and subsequent
isocyclic ring opening of pheophorbide 15 with ethylene diamine to give 16, followed by
coupling of the carboxylate of a second amino acid to the free amine group of the resulting
chlorin derivative, to give 17 (Scheme 3), or 2) selective esterification of the acetic acid side
chain (152 ester) of chlorin e6 (1) followed by coupling with two equivalents of an identical
amino acid to afford the 131,173-di(amino acid) derivative (Scheme 4).
In the first method, pheophorbide a (14) can be obtained by selective hydrolysis of the
phytyl ester group of pheophytin a (obtained from Spirulina maxima or S. pacifica alga32)
using a procedure developed by Wasielewski and Svec.33 Then the amino acid can be
coupled to the propionic side chain to obtain the pheophorbide derivative 15. The
pheophorbide isocyclic ring in 15 can be cleaved, using ethylene diamine,34 to provide 16
bearing a tethered free amine group able to couple with the carboxylic group of a second
(potentially different) amino acid.

Author Manuscript

The key step in the second method (Scheme 4) is the selective protection of the acetic acid
side chain of chlorin e6 (1) in the presence of the formic and propionic carboxylic side
chains. From the previous work, it was found that the acetic acid group of chlorin e6 can be
activated selectively by forming a cyclic anhydride. Chlorin e6 was activated using one
equivalent of DCC and DMAP to form the anhydride intermediate (6).24 Formation of cyclic
anhydride 6 can be confirmed by using UV-Vis spectroscopy. Then freshly prepared 0.5 M
sodium methoxide was added until the color of the reaction mixture changed from brownpurple to dark green. Mass spectroscopy confirmed the formation of desired product 18.
Purification of di-acid 18 was challenging due to its high polarity. After work-up it was
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possible to obtain a 1H NMR spectrum of the crude product and this was clear enough to
identify the unique peak for the 152 methyl ester, and indicated it was sufficiently pure for
the next step. Appearance of a new peak at 3.7 ppm for 3 protons provided evidence that
esterification took place uniquely at the acetic acid side chain. Then tert-butyl-protected
aspartic acid was coupled with crude 152-chlorin e6 monomethyl ester (18). The optimal
yield was obtained with HOBt and TBTU as coupling reagents at room temperature for 48
hours.35 This reaction was monitored by TLC. The product was purified via silica gel
column chromatography and the first moving band with 5% methanol/DCM was collected.
The structure of product 20 was confirmed by mass and 1H NMR spectroscopy. Purified tertbutyl protected diaspartyl chlorin e6 20 was treated with TFA/CH2Cl2 mixture for six hours
at room temperature to deprotect all four carboxylic acid groups. Pure compound 13 was
obtained after removal of TFA. The final product, 131,173-diaspartyl chlorin e6 13, was
obtained in 28% yield over four steps (Scheme 5).

Author Manuscript

Synthesis of 131,152-di(amino acid) chlorin e6 derivatives
Previous studies have revealed that the formic and acetic acid derivatives of chlorin e6 are
more potent photosensitizers than the propionic acid conjugates.27 Thus it was assumed that
the 131,152-di(amino acid) derivatives may show more potent photosensitizing ability in this
di(amino acid) series compared to the two other regioisomers (Figure 1). Therefore two
different amino acid conjugates of the 131,152 regioisomer were synthesized.

Author Manuscript

The main challenge was to protect the propionic side chain in the presence of the two other
carboxyl groups. There is no known chemical method to selectively methylate the propionic
side chain of chlorin e6 without methylating the acetic side chain. Esterification with
methanol under acidic conditions will form the 152,173-chlorin e6 dimethyl ester.36
Diazomethane will methylate all three carboxylic groups to form chlorin e6 trimethyl ester.37
But in the recent literature there is a reported chemo-selective aminolysis of the β-keto ester
of methyl pheophorbide a (21).38-40 This opens up a new route to synthesize 131,152 chlorin
e6 derivative from methyl pheophorbide a (21).

Author Manuscript

Previously, Shinoda and Osuka reported a facile transesterification of the β-keto ester of
methyl pheophorbide a.41 These authors were able to introduce various alcohols and steroid
groups in the presence of 2-chloro-1-methylpyridinium iodide (CMPI) and of 4-(N,Ndimethylamino)pyridine (DMAP) to the 132-position of pheophorbide. Haavikko and
coworkers also reported a selective aminolysis of the β-keto ester of the methyl
pheophorbide a (21).38 They used various primary, secondary and aromatic amines for the
aminolysis of the β-keto ester. It is known that aminolysis of the β-keto ester is usually facile
compared to inactivated esters.42,43 In the previous literature the formation of βenaminoesters by reaction between secondary amines and β-ketoesters at low temperatures
is described.44 It was noticed that at higher temperatures they tend to form substantial
amounts of the corresponding β-ketoamide along with the expected enamino-ester.
We have observed the same behavior with pheophorbide a.27 In our previous work,25 it was
possible to open the isocylic ring of pheophorbide a (by cleaving the β-keto ester) using
ethylene diamine at room temperature. It was noticed that at higher temperatures (90 °C in
toluene) the reaction with ethylene diamine tended to form two major products (two new
Org Biomol Chem. Author manuscript; available in PMC 2017 January 21.

Jinadasa et al.

Page 8

Author Manuscript

very close spots in TLC). Both products were isolated using preparative TLC and
characterized by 1H NMR and mass spectroscopy. One of the products still clearly shows the
unique peak for the pheophorbide isocylic ring: the proton appears as a sharp singlet at δ
6.26 (Figure 2). The disappearance of the peak for the methyl group of the β-ketoester and
new peaks for the ethylene diamine methylene groups confirmed the formation of βketoamide 22. The second product was identified as the expected chlorin e6 derivative 23. As
reported in the literature, temperature and the concentration of the amine play vital roles in
deciding the major product.38 A large excess of amine and mild heating always produced the
classical ring-opened product 23, and a stoichiometric amount of amine in refluxing toluene
yielded β-ketoamide 22 as the major product.

Author Manuscript

The first attempt to introduce the ethylene diamine to both ester and keto groups of methyl
pheophorbide 21 to form the 131,152-disubstituted chlorin e6 derivative 23 was unsuccessful.
Both β-keto-ester aminolysis and ring-opening reactions were attempted in one pot. First
methyl pheophorbide 21 and ethylene diamine were refluxed in toluene until disappearance
of the starting material, as monitored by TLC. Then excess amine was added and the
mixture was stirred at 40 °C for 12 hours to complete the ring cleavage reaction.
Unfortunately, this process resulted in a mixture of compounds, including the desired
product 23. Mass spectrometry revealed three major compounds (22-24) in this mixture, as
shown in Scheme 6. Purification of these compounds was challenging due to the high
polarity of the free amine groups.

Author Manuscript

It was decided to use half-protected ethylene diamine to simplify the purification process. As
indicated by TLC, aminolysis of the β-keto-ester of methyl pheophorbide a (21) with
protected ethylene diamine was completed after 12 hours. But the second step ring-cleavage
was unsuccessful with Boc-protected ethylene diamine, possibly due to steric bulkiness of
the amine. Thus, product 25 was isolated and purified before going on to the ring cleavage
reaction. As it was possible to achieve the isocyclic ring cleavage using free ethylene
diamine, unprotected ethylene diamine was used for the second step and the diethylene
diamine substituted product 26 was obtained. Product 26 was purified using a short silica gel
column and its identity was confirmed using mass and 1H NMR spectroscopy. Boc
deprotection was achieved using TFA to obtain the free amines (23) for the subsequent
coupling reaction. Coupling with protected aspartic acid, to give 27 followed by
deprotection produced the desired product 28, in 15% yield over 5 steps from methyl
pheophorbide a (21) (Scheme 7).
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Advantage was taken of a previous route to introduce two types of amino acids to the 131
and 152 positions. Protected β-alanine was used for the aminolysis reaction of 21 as it
greatly reduces the unwanted ring-opened product and creates a carboxylic end to couple
aspartic acid through its amino group. Subsequent aminolysis with protected β-alanine, to
give 29, followed by deprotection of the tert-butyl ester provided free acid 30. Its identity
was confirmed by mass spectrometry. Free acid 30 was activated and coupled with protected
aspartic acid to obtain pheophorbide derivative 31. This was purified and characterized
by 1H NMR and mass spectroscopy. A classical ring-opening reaction was performed with
excess ethylene diamine in toluene at 40 °C to provide the chlorin e6 derivative 32. The
reaction was monitored using UV-Vis spectroscopy, and the color changed from dark green
Org Biomol Chem. Author manuscript; available in PMC 2017 January 21.

Jinadasa et al.

Page 9

Author Manuscript

to bright green during isocyclic ring-opening. 1H NMR spectroscopy shows the new peaks
for ethylene diamine and mass spectroscopy confirmed the identity of the product. Then
Boc-protected lysine was coupled with the free amine group of chlorin e6 derivative 32 to
produce the desired 131-ethylenediaminyl-lysyl-152-β-alanylaspartylchlorin e6 tert-butyl
methyl ester. This product was purified using silica gel chromatography. Finally, global
deprotection with TFA in CH2Cl2 produced the final product 33 in 9% yield over six steps
starting from methyl pheophorbide a (21) (Scheme 8).
Cell Culture Studies

Author Manuscript

Cytotoxicity—The dark cytotoxicity and phototoxicity (~1.5 J/cm2) of chlorin e6 (1) and
its di(amino acid) conjugated derivatives 12, 13, 28 and 33 were evaluated in HEp2 cells
using a Cell Titer Blue assay. Significant differences were observed in the dark and
phototoxicity of the di(amino acid) conjugates, as shown in Table 1. These differences are
attributed to both the sites of conjugation (131,152 or 131,173 or 152,173) and the overall
charge and amphiphilic character of the chlorin e6 derivatives. While conjugation of two
aspartate groups via their α-amine groups gave tetra-anionic conjugates 12 and 13, the
conjugation of two aspartates via the carboxylate groups gave zwitterionic 28. On the other
hand compound 33 bearing an aspartate conjugated via the α-amine group and a lysine
conjugated via the carboxylate group, is also zwitterionic.

Author Manuscript

In comparison with chlorin e6 (1), the zwitterionic 131,152-disubstituted conjugates 28 and
33 showed higher phototoxicity while the tetra-anionic 12 and 13 showed lower
phototoxicity. These results are in agreement with our previous observations that 131- and
152-mono(amino acid) chlorin e6 derivatives tend to show higher phototoxicities than the
corresponding 173 derivatives.27 This might in part be due to the different molecular
conformations conferred by 131, 152 or 173 substitutions; while the 173 derivatives tend to
assume L-shape conformations with the side group positioned perpendicular, or folded over
the macrocycle, the 152 and in particular the 131 derivatives tend to assume linear
conformations with the side groups extending away from the macrocycle.27 Such linear
conformations might favor binding to specific intracellular components, inducing higher
phototoxicity. However, the zwitterionic 131,152 conjugates also showed about 5-fold higher
dark cytotoxicity than chlorin e6 and the tetra-anionic conjugates, and lower dark/photo
cytotoxicity ratio. The observed higher dark and photo cytotoxicities of conjugates 28 and
33 might in part be due to their higher cellular uptake (see below).

Author Manuscript

Time-dependent Cellular Uptake—The results obtained for the time-dependent uptake
of chlorin e6 and its di(amino acid) derivatives at a concentration of 10 μM in human
carcinoma HEp2 cells are shown in Figure 3. Conjugates 12 and 13 showed similar uptake
to chlorin e6, probably due to their low interaction and low permeability across the cell
membrane as a result of their negative charge. In addition to phosphate groups, the plasma
membranes of tumor cells generally contain higher net negative charge compared with
normal cells because of over-expression of polysialic acid residues.45 On the other hand, the
zwitterionic conjugates 28 and 33, showed much higher cellular uptake at all time points
investigated, and after 24 h about 4-fold and 6-fold higher cellular uptake were observed for
28 and 33 than chlorin e6, respectively. Although the 131,152-substituted conjugates 28 and
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33 were found to have similar cytotoxicities (see Table 1), conjugate 33 bearing two
different amino acid residues, lysine and aspartate, had significant higher uptake than 28 at
all times investigated, maybe due to its higher amphiphilicity conferred by substitution with
two different amino acids.

Author Manuscript

The preferential sites of subcellular localization of the di(amino acid) conjugates of chlorin
e6 were evaluated by fluorescence microscopy, and the results are shown in Table 2 and
Figures 4-7. The organelle specific probes BODIPY Ceramide (Golgi), LysoSensor Green
(Lysosomes), MitoTracker Green (mitochondria), and ER tracker Blue/White fluorescence
(ER) were used in the overlay experiments. All conjugates localized in the lysosomes and
the Golgi apparatus, and to a smaller extent in the ER. In addition, conjugate 33 bearing
lysine and aspartate residues, was also observed in mitochondria, and this might in part be
responsible for its higher dark and phototoxicities. These results are in agreement with the
known preferential localization of LS-11 (152-aspartyl chlorin e6) in the lysosomes,46 and
with our previous observations of 131, 152 and 173 mono(amino acid) conjugates of chlorin
e6 localizing in lysosomes, ER and Golgi.27

Experimental
General

Author Manuscript

All air and moisture sensitive reactions were performed in dried and distilled solvents under
an argon atmosphere. All solvents and reagents were purchased from commercial sources,
unless otherwise stated. Silica gel 60 (230×400 mesh, Sorbent Technologies) was used for
column chromatography. Analytical thin-layer chromatography (TLC) was carried out using
polyester backed TLC plates 254 (precoated, 200 μm) from Sorbent Technologies. NMR
spectra were recorded on an AV-400 spectrometer (400 MHz for 1H, 100 MHz for 13C). The
chemical shifts are reported in δ ppm using the following partially deuterated solvents as
internal references: CD2Cl2 5.32 ppm (1H), 54 ppm (13C); d-DMSO 2.49 ppm (1H), 39.5
ppm (13C); d-CH3OH 4.78 ppm (1H), 49.0 ppm (13C); CDCl3 7.26 ppm (1H), 77.16 ppm
(13C); (CH3)2CO 2.50 ppm (1H), 29.84 ppm (13C). Electronic absorption spectra were
measured on an Agilent 8453 UV/Vis spectrophotometer. Mass spectra were obtained on a
Bruker Omniflex MALDI Time-of-Flight Mass Spectrometer. Spirulina pacifica alga was
purchased as a spray-dried powder from Cyanotech, Hawaii. Pheophytin a (1) was extracted
from Spirulina pacifica alga as previously published and its spectroscopic characterization
agreed with the published data.34 All compounds synthesized were purified and isolated in ≥
95% purity, as evidenced by analytical TLC in at least two solvent systems, and confirmed
by the absence of extraneous tetrapyrrole resonances in 1H- and 13C-NMR spectra.

Author Manuscript

Synthetic procedures and characterization
152,173-Diaspartylchlorin e6 tetra(tert-butyl)-monomethyl ester (11)—Chlorin e6
(1, 100 mg, 0.168 mmol) was dissolved in dry CH2Cl2 (7 mL) and DIEA (0.06 mL, 0.34
mmol) was added. A mixture of DCC (105 mg, 0.51 mmol) and DMAP (163 mg, 0.51
mmol) in CH2Cl2 (8 mL) was added and the mixture was allowed to stir for 2 h. Then
aspartic acid di(tert)butyl ester hydrochloride (125 mg, 0.445 mmol) and DIEA (0.075 ml)
were mixed in CH2Cl2 (2 ml) and added to the reaction mixture. The solution was allowed
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to stir overnight at room temperature and after 12 h it was treated with excess ethereal
diazomethane. Then the mixture was diluted with CH2Cl2 and washed with 5% aqueous
citric acid, followed by a wash with brine and finally water. It was dried over anhydrous
Na2SO4 and the solvent was evaporated. The residue was dissolved in 5% methanol/CH2Cl2
and purified via silica gel column chromatography with the same mobile phase to afford
152,173-diaspartylchlorin e6 tera(tert-butyl)-monomethyl ester (11 , C59H80N6O12, 54 mg,
0.051 mmol, 30% yield); UV-Vis (acetone): λmax (ε/mM−1cm−1) 664 nm (52), 608 (3.9),
528 (3.6), 500 (13), 400 (170); 1H NMR (acetone-d6, 400 MHz): δ 9.80 (s, 1H), 9.63 (s,
1H), 9.06 (s, 1H), 8.15 (dd, J = 17.9, 11.6 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 8.0
Hz, 1H), 6.37 (dd, J = 17.9, 1.5 Hz, 1H), 6.10 (dd, J = 11.6, 1.4 Hz, 1H), 5.37 (d, J = 12.0
Hz, 2H), 4.67 (s, 2H), 4.26 (s, 3H), 3.77 (d, J = 7.6 Hz, 2H), 3.57 (s, 3H), 3.48 (s, 4H), 3.25
(s, 3H), 2.83 – 2.63 (m, 3H), 2.52 – 2.28 (m, 2H), 2.14 (s, 2H), 1.89 – 1.79 (m, 2H), 1.78 (d,
J = 7.1 Hz, 3H), 1.69 (t, J = 7.6 Hz, 3H), 1.43 (s, 9H), 1.35 (s, 9H), 1.26 (s, 9H), 1.16 (s,
9H), −1.36 (s, 1H), −1.57 (s, 1H); MS (MALDI-TOF) m/z 1065.591 [M+H]+, calcd. for
C59H81N6O12 1065.591.

Author Manuscript

152,173-Diaspartylchlorin e6 methyl ester (12)—152,173-Diaspartylchlorin e6
tetra(tert-butyl)-monomethyl ester (11, 54 mg, 0.051 mmol) was dissolved in 2 mL of dry
CH2Cl2 in an ice bath under argon and TFA (1 mL) was added and the reaction mixture was
allowed to stir overnight. The solvent was rotevaporated several times with diethyl ether to
remove residual TFA. The residue was washed with CH2Cl2 several times. The final product
was re-dissolved in a water/acetonitrile mixture and freeze dried to afford 152,173diaspartylchlorin e6 methyl ester (12, C43H48N6O12, 38 mg, 0.045 mmol, 88% yield); UVVis (MeOH): λmax (ε/mM−1cm−1) 661 nm (71.6), 607 (11), 527 (9.3), 499 (22.4), 399
(172.3); 1H NMR (acetone-d6, 400 MHz): δ 9.88 (s, 1H), 9.66 (s, 1H), 9.21 (s, 1H), 8.11
(dd, J = 17.8, 11.6 Hz, 1H), 6.35 (d, J = 17.8 Hz, 1H), 6.14 (d, J = 11.6 Hz, 1H), 5.35 (t, J =
22.7 Hz, 2H), 4.81 (br. s, 1H), 4.65 (br. s, 1H), 4.63 (br. S, 1H), 4.25 (s, 3H), 3.70 (d, J = 7.9
Hz, 2H), 3.54 (s, 3H), 3.46 (s, 3H), 3.18 (s, 3H), 3.06 – 2.60 (m, 5H), 2.27 (m, 2H), 1.81 (d,
J = 7.1 Hz, 3H), 1.55 (t, J = 7.4 Hz, 3H). 2.00 – 1.50 (m, 4H) 1.25 (m, 2H); 13C NMR
(acetone-d6, 101 MHz) δ 193.12, 192.77, 191.95, 191.88, 191.84, 191.04, 188.72, 168.55,
164.14, 163.25, 160.42, 158.10, 157.50, 155.68, 155.26, 155.20, 151.92, 150.02, 149.04,
145.83, 142.64, 137.66, 134.79, 124.88, 121.07, 117.59, 116.00, 73.49, 73.03, 69.43, 69.24,
68.92, 59.56, 55.70, 53.44, 52.59, 50.75, 42.86, 39.10, 36.79, 31.75, 31.58, 30.41. MS
(MALDI-TOF) m/z 840.451 [M]+, calcd. for C43H49N6O12 840.333

Author Manuscript

131,173-Diaspartylchlorin e6 tetra(tert-butyl)-monomethyl ester (20)—Chlorin e6
(1, 100 mg, 0.168 mmol) was dissolved in methanol (5 mL). DCC (35 mg, 0.17 mmol) and
DMAP (21 mg, 0.17 mmol) were added and the mixture was stirred until the anhydride
intermediate was observed in the TLC. After 1 h, freshly prepared sodium methoxide (0.34
mL of a 0.5 M solution) was added into the reaction mixture dropwise until the color
changed from brown to light green. The reaction was monitored by UV-Vis spectroscopy.
The solution changed from brown to light green as the anhydride ring opened. The mixture
was diluted with ethyl acetate and then washed with 5% aqueous citric acid, followed by a
wash with brine and finally with water. It was dried over anhydrous Na2SO4 to afford
chlorin e6 152-methyl ester (18, C35H39N4O6, 101 mg, 0.165 mmol, 100% yield).
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Purification was challenging due to the polarity induced by the two free acid groups; thus,
the crude product was subjected to the next reaction without purification. A 1H NMR
spectrum of the crude product confirmed the methylated acetic side chain. [MS (MALDITOF) m/z 633.311 [M+Na]+, calcd. for C35H39N4O6 633.269]. Chlorin e6 monomethyl ester
(18, 101 mg, 0.165 mmol) was dissolved in dry DMF (5 mL). A mixture of HOBt (46 mg,
0.34 mmol), TBTU (109 mg, 0.34 mmol) and DIEA (0.06 ml, 0.34 mmol) in DMF (5 ml)
was added and the mixture was allowed to stir for 30 min at room temperature. Then aspartic
acid di-tert-butyl ester hydrochloride (125 mg, 0.445 mmol) and DIEA (0.08 ml, 0.445
mmol) were mixed in CH2Cl2 (2 mL) and added to the reaction mixture. The solution was
allowed to stir for 48-72 h until formation of the desired product was confirmed by TLC.
Then the reaction mixture was washed with 5% aqueous citric acid, followed by a wash with
brine and then water. The organic phase was dried over anhydrous Na2SO4 and solvent was
evaporated. The residue was dissolved in 5% methanol/CH2Cl2 and purified via
chromatography on a short silica gel column with the same mobile phase to afford 152,173diaspartylchlorin e6 tetra(tert-butyl)-monomethyl ester (20, C59H80N6O12, 85 mg, 0.079
mmol, 48% yield); UV-Vis (acetone): λmax (ε/mM−1cm−1) 663 nm (54), 607 (3.8), 528
(3.1), 500 (13), 399 (165); 1H NMR (acetone-d6, 400 MHz): δ 9.79 (d, J = 6.1 Hz, 1H), 9.65
(s, 1H), 9.10 (s, 1H), 8.42 (d, J = 7.9 Hz, 1H), 8.12 (dd, J = 17.8, 11.6 Hz, 1H), 7.29 (d, J =
8.2 Hz, 1H), 6.32 (d, J = 17.8 Hz, 1H), 6.06 (d, J = 11.4 Hz, 1H), 5.73 (d, J = 18.9 Hz, 1H),
5.50 – 5.21 (m, 2H), 4.76 – 4.61 (m, 2H), 4.61 – 4.48 (m, 1H), 3.76 (s, 3H), 3.74 – 3.68 (m,
1H), 3.65 (s, 3H), 3.47 (s, 3H), 3.42 (s, 1H), 3.22 (s, 3H), 3.20 – 3.11 (m, 2H), 2.66 (d, J =
5.2 Hz, 2H), 2.46 – 2.27 (m, 1H), 2.24 – 2.14 (m, 1H), 1.83 – 1.72 (m, 2H), 1.66 (s, 9H),
1.55 (s, 9H), 1.41 (s, 9H), 1.35 (s, 9H), 1.72-1.2 (m, 6H), −1.66 (1H), −1.85 (1H); MS
(MALDI-TOF) m/z 1065.681 [M+H]+, calcd. for C59H81N6O12 1065.591.
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131,173-Diaspartylchlorin e6 methyl ester (13)—152,173-Diaspartylchlorin e6
tetra(tert)butyl methyl ester (20, 50 mg, 0.047 mmol) was dissolved in 2 mL of dry CH2Cl2
in an ice bath under argon. TFA (1 mL) was added and the reaction mixture was allowed to
stir overnight. The mixture was rotavaporated several times with diethyl ether to remove
residual TFA. The residue was dissolved in water/acetonitrile mixture and freeze dried to
obtain 131,173-diaspartylchlorin e6 methyl ester (13, C43H48N6O12, 21 mg, 0.025 mmol,
53%). UV-Vis (MeOH): λmax (ε/mM−1cm−1) 662 nm (75.3), 607 (23), 529 (10), 500 (8.3),
400 (165.2); 1H NMR (MeOD, 400 MHz) δ 10.07 (s, 1H), 9.86 (s, 1H), 9.45 (s, 1H), 8.06
(dd, J = 17.3, 11.9 Hz, 1H), 6.30 (d, J = 17.8 Hz, 1H), 6.24 (d, J = 11.4 Hz, 1H), 5.62 (d, J =
18.9 Hz, 1H), 5.28 (d, J = 18.3 Hz, 2H), 4.78 – 4.76 (m, 2H), 4.76 - 4.56 (m, 3H), 3.80 (s,
3H), 3.59 (s, 3H), 3.52 (s, 3H), 3.21 (s, 3H), 2.87 – 2.69 (m, 2H), 2.68 – 2.47 (m, 1H), 2.21
(d, J = 19.9 Hz, 2H), 1.94 – 1.72 (m, 4H), 1.59 (d, J = 6.9 Hz, 4H), 1.30 – 1.01 (m, 4H). 13C
NMR (MeOD, 101 MHz) δ 175.33, 174.90, 174.72, 174.02, 173.88, 173.83, 173.66, 169.35,
143.94, 142.95, 142.47, 140.57, 140.42, 138.22, 138.01, 136.12, 135.46, 135.25, 133.96,
132.61, 131.29, 129.47, 124.69, 107.02, 100.12, 98.81, 97.77, 54.94, 53.05, 51.25, 50.55,
38.89, 36.86, 34.68, 33.77, 26.68, 26.02, 23.70, 20.00, 16.98, 12.22, 10.91, 9.11. MS
(MALDI-TOF) m/z 840.532 [M]+, calcd. for C43H49N6O12 840.333.
Ethylenediaminyl(boc) pheophorbide a (25)—Methyl pheophorbide a (21, 100 mg,
0.165 mmol) was dissolved in dry toluene (20 ml) and the mixture was heated to 100 °C
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under nitrogen. Then, mono-boc protected ethylene diamine (32 mg, 0.20 mmol) was added.
The reaction mixture was allowed to stir overnight at 100 °C while monitoring by TLC.
Then the solvent was removed and the residue was dissolved in CH2Cl2 and washed with
5% aqueous citric acid, followed by water and brine. It was dried over anhydrous Na2SO4
and the solvent was evaporated. The residue was dissolved in 3% methanol/CH2Cl2 and
purified via silica gel column chromatography with the same mobile phase to afford
ethylenediaminyl(boc) pheophorbide a (25, C42H50N6O6, 80 mg, 0.109 mmol, 65%); UVVis (DCM): λmax (ε/mM−1cm−1) 667 nm (46), 609 (6.5), 535 (8), 505 (10), 413 (99); 1H
NMR (acetone-d6, 400 MHz) δ 9.58 (s, 1H), 9.30 (s, 1H), 8.87 (s, 1H), 8.13 – 7.92 (m, 2H),
6.27 (dd, J = 17.9, 1.5 Hz, 1H), 6.18 (s, 1H), 6.12 (dd, J = 11.5, 1.4 Hz, 1H), 6.16 (m, 1H),
4.77 – 4.55 (m, 1H), 4.37 (dt, J = 9.3, 2.5 Hz, 1H), 3.59 (s, 3H), 3.52 (s, 3H), 3.42 – 3.36 (m,
2H), 3.39 (s, 3H), 3.35 (d, J = 6.5 Hz, 3H), 3.08 (s, 3H), 2.74 – 2.57 (m, 2H), 2.46 – 2.33 (m,
1H), 2.31 – 2.19 (m, 1H), 1.84 (d, J = 7.3 Hz, 3H), 1.76 – 1.64 (m, 1H), 1.58 (t, J = 7.6 Hz,
3H), 1.35 (s, 9H), −1.77 – −2.11 (m, 2H); MS (MALDI-TOF) m/z 735.561 [M+H]+, calcd.
for C42H51N6O6 735.387
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152-Ethylenediaminyl(boc)-131-ethylenediaminylchlorin e6 methyl ester (26)—
Ethylenediaminyl(boc) pheophorbide-a (25, 80 mg, 0.109 mmol) was dissolved in toluene
(10 mL) and ethylene diamine (30 mg, 0.5 mmol) was added. The reaction mixture was
heated at 40 °C overnight. Progress was monitored by TLC and UV-Vis spectrometry. After
the reaction was complete by TLC, the solvent was removed and the residue was dissolved
in CH2Cl2 and washed with 5% aqueous citric acid to remove excess amine, followed by a
wash with brine. The organic phase was dried over anhydrous Na2SO4 and the solvent was
evaporated. The residue was dissolved in 5% methanol/CH2Cl2 and eluted from a silica gel
column with the same mobile phase. Then the methanol percentage of the mobile phase was
gradually increased up to 20% to elute the pure product from the column. The solvent was
evaporated and the residue was re-dissolved in 5% acetone/CH2Cl2 and filtered to remove
silica from the sample. After evaporation of the solvent pure 152-ethylenediaminyl(boc)-131ethylenediaminylchlorin e6 methyl ester was obtained (26, C44H58N8O6, 55 mg, 0.069
mmol, 64%); UV-Vis (acetone): λmax (ε/mM−1cm−1) 663 nm (55), 607 (2.6), 528 (1.3), 500
(12), 399 (170); 1H NMR (acetone-d6, 400 MHz) δ 9.74 (s, 1H), 9.73 (s, 1H), 9.13 (s, 1H),
8.36 (br. s, 1H), 8.23 (dd, J = 17.8, 11.5 Hz, 1H), 7.46 (br. s, 1H), 6.64 (br. s, 1H), 6.40 (dd, J
= 17.9, 1.5 Hz, 1H), 6.12 (dd, J = 11.7, 1.5 Hz, 1H), 5.55 (d, J = 18.0 Hz, 1H), 5.09 (d, J =
9.3 Hz, 1H), 4.76 – 4.51 (m, 2H), 4.28 (s, 1H), 4.01 – 3.83 (m, 1H), 3.80 – 3.67 (m, 4H),
3.58 (s, 3H), 3.54 (s, 3H), 3.52 (s, 3H), 3.29 (s, 3H), 3.25 – 3.16 (m, 2H), 3.08 (dd, J = 9.1,
4.9 Hz, 1H), 2.78 – 2.64 (m, 1H), 2.43 – 2.21 (m, 2H), 2.00 (d, J = 8.0 Hz, 1H), 1.76 (d, J =
7.1 Hz, 3H), 1.68 (t, J = 7.6 Hz, 3H), 1.20 (s, 9H), 0.97 (m, 3H), −1.66 (s, 1H), −2.02 (s,
1H); MS (MALDI-TOF) m/z 795.651 [M+H]+, calcd. for C44H59N8O6 795.456
131,152-Diethyleneaminylaspartylchlorin e6 di(tert)butyl di(boc) methyl ester
(27)—152-Ethylenediaminyl(boc)-131-ethylenediaminylchlorin e6 methyl ester (26, 55 mg,
0.069 mmol) was dissolved in 3 mL of dry CH2Cl2 in an ice bath under argon and 1 m of
TFA was added. Then the reaction mixture was allowed to stir overnight. The mixture was
rotavaporated several times with diethyl ether to remove residual TFA. The residue was
dissolved in water/acetonitrile mixture and freeze dried. Without any further purification the
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crude product was taken to the next step. (23, C39H50N8O4, 42 mg, 0.06 mmol, 88%), [MS
(MALDI-TOF) m/z 695.445 [M+H]+,calcd. for C39H51N8O4 695.403]. (Boc)Asp(tBu)OH
(70 mg, 0.24 mmol) was dissolved in dry DMF (5 mL). A mixture of HOBt (32 mg, 0.24
mmol), TBTU (77 mg, 0.24 mmol) and DIEA (0.05 ml, 0. mmol) in DMF (3 mL) was added
and the mixture was allowed to stir for 1 h. 131,152-Diethylenediaminylchlorin e6 methyl
ester (23, 42 mg, 0.060 mmol) was added to the reaction mixture and stirring was continued
for 48 h. The mixture was diluted with CH2Cl2 and then washed with 5% aqueous citric
acid, followed by washes with brine and water. The organic layer was dried over anhydrous
Na2SO4 and the solvent was evaporated. The residue was dissolved in 6% MeOH/CH2Cl2
and purified via silica gel column chromatography using the same mobile phase to afford
131,152-diethyleneaminyl-diaspartylchlorin e6 di(tert)butyl di(boc) methyl ester (27,
C65H92N10O14, 30 mg, 0.024 mmol, 40%); UV-Vis (acetone): λmax (ε/mM−1cm−1) 663 nm
(48), 607 (2.1), 528 (1.7), 500 (11), 399 (150); 1H NMR (chloroform-d, 400 MHz) δ 9.68 (s,
1H), 9.61 (s, 1H), 8.79 (s, 1H), 8.07 (dd, J = 17.9, 11.5 Hz, 1H), 7.97 (d, J = 5.7 Hz, 1H),
7.74 (s, 1H), 6.34 (d, J = 17.8 Hz, 1H), 6.13 (d, J = 11.5 Hz, 1H), 5.81 (d, J = 8.3 Hz, 1H),
5.47 (d, J = 18.1 Hz, 1H), 5.28 – 4.88 (m, 2H), 4.67 – 4.30 (m, 3H), 4.10 – 3.68 (m, 10H),
3.65 – 3.12 (m, 5H), 3.54 (s, 3H), 3.48 (s, 3H), 3.31 (s, 3H), 2.93 – 2.69 (m, 2H), 2.67 – 2.53
(m, 1H), 2.23 (m, 3H), 2.04 (s, 1H), 1.90 – 1.55 (m, 7H), 1.31 (s, 18H), 1.14 (s, 18H), 0.94 –
0.80 (m, 1H), −1.62 (s, 1H), −1.80 (s, 1H); MS (MALDI-TOF) m/z 1237.651 [M+H]+,
calcd. for C65H93N10O14 1237.687.
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131,152-Diethyleneaminyl-diaspartylchlorin e6 methyl ester (28)—131,152Diethyleneaminyl-diaspartylchlorin e6 di(tert)butyl di(boc) methyl ester (27, 30 mg, 0.024
mmol) was dissolved in 2 mL of dry CH2Cl2 in an ice bath under argon. TFA (1 mL) was
added and the reaction mixture was allowed to stir overnight. The reaction mixture was
rotavaporated several times with diethyl ether to remove residual TFA. The residue was
washed with CH2Cl2 several times. The final product was dissolved in water and freeze
dried to obtain 131-152-diethyleneaminyl-diaspartylchlorin e6 methyl ester (28,
C47H60N10O10, 16 mg, 0.016 mmol, 70%). UV-Vis (MeOH): λmax (ε/mM−1cm−1) 661 nm
(74.7), 606 (8.4), 527 (6.2), 500 (20.5), 400 (190.2); 1H NMR (methanol-d4, 400 MHz) δ
10.18 (s, 1H), 10.03 (s, 1H), 9.47 (s, 1H), 8.20 (dd, J = 17.7, 11.6 Hz, 1H), 6.39 (d, J = 17.8
Hz, 1H), 6.29 (d, J = 11.5 Hz, 1H), 5.59 (d, J = 18.7 Hz, 1H), 5.42 (d, J = 18.7 Hz, 1H), 4.79
(d, J = 7.2 Hz, 1H), 4.54 (d, J = 10.8 Hz, 1H), 4.44 (ddd, J = 24.1, 8.5, 4.2 Hz, 1H), 4.25 –
4.05 (m, 1H), 4.03 – 3.83 (m, 4H), 3.74 (s, 3H), 3.67 (s, 3H), 3.56 (s, 3H), 3.49 (td, J = 10.6,
9.5, 4.6 Hz, 2H), 3.41 – 3.26 (m, 6H), 3.38 (s, 3H), 3.23 – 3.00 (m, 2H), 2.99 – 2.82 (m,
2H), 2.70 (dd, J = 17.9, 9.0 Hz, 1H), 2.59 – 2.47 (m, 1H), 2.46 – 2.31 (m, 1H), 1.91 – 1.51
(m, 3H), 1.83 (d, J = 7.1 Hz, 3H), 1.68 (t, J = 7.3 Hz, 3H), 1.29 (m, 3H); 13C NMR (MeOD,
101 MHz) δ 174.42, 173.97, 173.75, 172.86, 171.55, 171.39, 169.05, 168.72, 168.05,
143.07, 142.13, 141.77, 139.03, 138.76, 137.66, 136.98, 135.23, 134.58, 132.81, 131.33,
130.49, 128.33, 123.54, 105.19, 99.20, 97.43, 97.06, 53.90, 51.08, 49.96, 49.13, 39.50,
39.30, 39.19, 38.70, 34.67, 34.46, 30.47, 29.65, 29.30, 22.83, 22.37, 18.95, 15.79, 11.06,
10.88, 9.85. MS (MALDI-TOF) m/z 947.559 [M+Na]+, calcd. for C47H60N10NaO10
947.439.
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β-Alanylpheophorbide a tert-butyl methyl ester (29)—Methyl pheophorbide a (21,
100 mg, 0.165 mmol) was dissolved in dry toluene (10 mL) and the mixture was heated to
100 °C under nitrogen. Then β-alanine(tBu).HCl (45 mg, 0.25 mmol) and DIEA (0.06 ml,
0.33 mmol) were added. The reaction mixture was allowed to stir overnight at 100 °C in an
oil bath and was monitored by TLC. Then the solvent was removed and the residue was
dissolved in CH2Cl2 and washed with 5% aqueous citric acid followed by water and with
brine. The organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated.
The residue was dissolved in 5% methanol/CH2Cl2 and purified via silica gel
chromatography with the same mobile phase and to afford β-alanylpheoporbide a tert-butyl
methyl ester (29, C42H49N5O6, 65 mg, 0.090 mmol, 54%); UV-Vis (DCM): λmax (ε/
mM−1cm−1) 667 nm (45), 609 (6.5), 535 (7.6), 505 (10.5), 412 (107); 1H NMR (acetone-d6,
400 MHz) δ 9.33, 9.23* (s, 1H), 8.99, 9.93* (s, 1H), 8.79, 8.77* (s, 1H), 7.97*, 7.92 (t, J =
6.0 Hz, 1H), 7.80 (m, 1H), 6.16, 6.13* (s, 1H), 6.07 (d, J = 9.7 Hz, 1H), 5.99 (dd, J = 11.6,
1.5 Hz, 1H), 4.65*, 4.57 (qd, J = 7.4, 2.0 Hz, 1H), 4.38 (tt, J = 9.7, 2.2 Hz, 1H), 3.68 (qd, J =
6.6, 2.3 Hz, 1H), 3.61 (q, J=6.4, 1H) 3.59*, 3.53 (s, 3H), 3.49 (s, 3H), 3.41 (s, 2H), 3.28*,
3.27 (s, 3H), 2.86*, 2.84 (s, 3H), 2.79 (m, 2H), 2.71 – 2.52 (m, 2H), 2.49 – 2.12 (m, 2H),
1.85 (d, J = 7.3 Hz, 3H), 1.64 (t, J = 7.3 Hz, 3H), 1.48*, 1.49 (s, 9H), −2.00 (s, 1H), −2.16 (s
1H).(* Minor 132 epimer); MS (MALDI-TOF) m/z 720.467 [M+H]+, calcd. for
C42H50N5O6 720.368.
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β-Alanylaspartylpheoporbide a di-tertbutyl methyl ester (31)—βAlanylpheophorbide a tert-butyl methyl ester (29, 65 mg, 0.090 mmol) was dissolved in 2
mL of dry CH2Cl2 in an ice bath under argon. TFA (1 mL) was added and the reaction
mixture was allowed to stir for 6 h. The reaction mixture was diluted with CH2Cl2 and
washed with water and then with saturated sodium bicarbonate. This formed a precipitate
while washing with sodium bicarbonate then citric acid solution was added until the
precipitate dissolved in the organic phase. Then the solution was washed with brine and
dried over anhydrous Na2SO4 to give β-alanylpheoporbide a methyl ester (30, C38H41N5O6,
60 mg, 0.09 mmol, 100%). [MS (MALDI-TOF) m/z 686.387 [M+H]+, calcd. for
C38H41N5NaO6 686.295]. β-Alanylpheoporbide a methyl ester (30, 60 mg, 0.090 mmol)
was dissolved in dry DMF (5 mL). A mixture of HOBt (18 mg, 0.135 mmol), TBTU (43 mg,
0.135) and DIEA (0.03 ml, 0.18 mmol) in DMF (3 mL) was added and the mixture was
allowed to stir for 30 min. Then a mixture of aspartic acid di(tert)butyl ester hydrochloride
(101 mg, 0.36 mmol) and DIEA (0.06 ml, 0.36 mmol) in CH2Cl2 (3 mL) was added to the
reaction mixture. The mixture was allowed to stir for 24 h. The mixture was diluted with
CH2Cl2 and then washed with 5% aqueous citric acid, followed by with water and brine.
The organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated. The
residue was dissolved in 5% methanol/CH2Cl2 and purified via silica column
chromatography with the same mobile phase to afford β-alanyl aspartyl pheophorbide a ditertbutyl methyl ester (31, C50H62N6O9, 48 mg, 0.053 mmol, 59%); UV-Vis (DCM): λmax
(ε/mM−1cm−1) 667 nm (41.5), 609 (5.5), 535 (7), 505 (10), 413 (103); 1H NMR (acetone-d6,
400 MHz) δ 9.06, 8.98* (s, 1H), 8.70, 8.59* (s, 1H), 8.69 (s, 1H), 8.2* 8.06 (t, J = 5.9 Hz,
1H), 7.70 – 7.45 (m, 2H), 6.17, 6.08* (s, 1H), 5.93 (dt, J = 17.7, 2.3 Hz, 1H), 5.85 (dd, J =
11.5, 1.4 Hz, 1H), 4.82*, 4.76 (dt, J = 8.3, 5.8 Hz, 1H), 4.64*, 4.55 (tt, J = 9.0, 4.5 Hz, 1H),
4.42*, 4.35 (dt, J = 9.7, 2.5 Hz, 1H), 3.77 (q, J = 6.5 Hz, 2H), 3.63*, 3.59 (s, 3H), 3.42,
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3.31* (s, 3H), 3.14 (s, 3H), 3.05 (h, J = 6.8, 6.3 Hz, 3H), 2.78 (dd, J = 5.9, 4.7 Hz, 2H), 2.74
– 2.66 (m, 4H), 2.63 (s, 3H), 2.49 – 2.37 (m, 1H), 2.20 (td, J = 9.0, 3.3 Hz, 1H), 1.85, 1.65*
(d, J = 7.3 Hz, 3H), 1.45 (s, 9H), 1.42 (s, 9H), 1.35 (t, J = 7.5 Hz, 2H), −2.17*, −2.33 (s,
2H). ).(* Minor 132 epimer); MS (MALDI-TOF) m/z 890.461 [M]+, calcd. for C50H63N6O9
890.458.
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131-Ethylenediaminyl-152-β-alanylaspartylchlorin e6 di-tert-butyl methyl ester
(32)—β-Alanylaspartylpeoporbide a di-tert-butyl methyl ester (31, 48 mg, 0.053 mmol) was
dissolved in toluene (10 ml) and ethylenediamine (15 mg, 0.26 mmol) was added. The
reaction mixture was heated at 40 °C for 24-36 h. It was monitored by TLC and UV-Vis
spectroscopy. After reaction was complete as monitored by TLC, the solvent was removed
and the residue was dissolved in CH2Cl2 and washed with 5% aqueous citric acid to remove
excess amine, followed by a wash with brine. The organic phase was dried over anhydrous
Na2SO4 and the solvent was evaporated. The residue was dissolved in 5% methanol/CH2Cl2
and chromatographed on a silica gel column with the same mobile phase. Then the methanol
percentage of the mobile phase was gradually increased up to 20% to elute the pure product
from the column. The solvent was evaporated and re-dissolved in 5% acetone/CH2Cl2 and
filtered to remove silica from the sample. After evaporation of solvent 131ethylenediaminyl-152-β-alanyl aspartylchlorin e6 di-tert-butyl methyl ester was obtained (32,
C52H70N8O9, 30 mg, 0.031 mmol, 58 %). UV-Vis (acetone): λmax (ε/mM−1cm−1) 664 nm
(51.5), 607 (2.5), 528 (2), 500 (11), 400 (160); It was not possible to obtain the 1H NMR
spectrum and so the crude product was subjected directly to next step. MS (MALDI-TOF)
m/z 951.767 [M+H]+, calcd. for C52H71N8O9 951.534.
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131-Ethylenediaminyllysinyl-152-β-alanylaspartylchlorin e6 methyl ester (33)
via 132-ethylenediaminyllysinyl-152-β-alanylaspartylchlorin e6 di-tert-butyl di(boc) methyl ester—Boc-Lys(Boc)OH.DCHA (61 mg, 0.116 mmol) was dissolved in dry
DMF (5 mL). A mixture of HOBt (16 mg, 0.116 mmol), TBTU (37 mg, 0.116 mmol) and
DIEA (0.024 ml, 0.14 mmol) in DMF (3 mL) was added and the mixture was stirred for 30
min. 131-Ethylenediaminyl-152-β-alanylaspartylchlorin e6 di-tertbutyl methyl ester (32, 30
mg, 0.031 mmol) was added to the reaction mixture and it was stirred for 72 h. After the
reaction was deemed complete by TLC, the mixture was diluted with CH2Cl2 and then
washed with 10% sodium bicarbonate, 5% aqueous citric acid, then followed by washing
with brine. The organic phase was dried over anhydrous Na2SO4 and the solvent was
evaporated. The residue was dissolved in 10% MeOH/CH2Cl2 and purified via silica gel
column chromatography using the same mobile phase to afford 131ethylenediaminyllysinyl-152-β-alanylaspartylchlorin e6 di-tert-butyl di-tert-butyl carbamates
methyl ester (C68H98N10O14, 24 mg, 0.018 mmol, 61%); UV-Vis (acetone): λmax (ε/
mM−1cm−1) 663 nm (43.5), 607 (3), 528 (2.5), 500 (10), 400 (136); 1H NMR (acetone-d6,
400 MHz) δ 9.67 (s, 1H), 9.65 (s, 1H), 9.10 (s, 1H), 8.71 (s, 1H), 8.26 (d, J = 5.5 Hz, 1H),
8.17 (dd, J = 17.8, 11.5 Hz, 1H), 7.05 (s, 2H), 6.34 (d, J = 17.8 Hz, 1H), 6.23 (d, J = 8.0 Hz,
1H), 6.07 (d, J = 11.5 Hz, 1H), 5.95 (s, 1H), 5.56 (d, J = 18.9 Hz, 1H), 5.22 (d, J = 19.2 Hz,
1H), 4.68 (q, J = 7.1 Hz, 1H), 4.54 (d, J = 9.6 Hz, 1H), 4.29 (q, J = 3.6 Hz, 1H), 3.98 – 3.62
(m, 9H), 3.57 (s, 3H), 3.48 (s, 6H), 3.25 (s, 3H), 3.02 (d, J = 6.0 Hz, 2H), 2.92 (s, 3H), 2.56
– 2.40 (m, 2H), 2.40 – 2.26 (m, 2H), 2.26 – 2.17 (m, 1H), 1.91 (dt, J = 23.0, 8.6 Hz, 2H),
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1.74 (d, J = 7.1 Hz, 3H), 1.66 (t, J = 7.2 Hz, 3H), 1.57 – 1.44 (m, 4H), 1.37 (s, 18H), 1.34 (s,
18H), −1.65 (s, 1H), −1.94 (s, 1H); MS (MALDI-TOF) m/z 1279.775 [M+H]+, calcd. for
C68H99N10O14 1279.734.
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The abovementioned 131-ethylenediaminyllysinyl-152-β-alanylaspartylchlorin e6 ditertbutyl di-(boc) methyl ester (24 mg, 0.018 mmol) was dissolved in 2 mL of dry CH2Cl2 in
an ice bath under argon. TFA (1 mL) was added and the reaction mixture was allowed to stir
overnight. The mixture was rotavaporated several times with diethyl ether to remove TFA
and the residue was washed with CH2Cl2 several times. The final product was dissolved in
water and then freeze dried to obtain 131-ethylenediaminyllysinyl-152-βalanylaspartylchlorin e6 methyl ester (33, C50H66N10O10, 14 mg, 0.014 mmol; 79%). UVVis (MeOH): λmax (ε/mM−1cm−1) 658 nm (18.9), 635 (67.8), 594 (14), 511 (10), 411
(150.8); 1H NMR (400 MHz, MeOD) δ 9.96 (s, 1H), 9.70 (s, 1H), 9.42 (s, 1H), 7.98 (s, 2H),
6.39 – 6.01 (m, 3H), 5.57 (d, J = 18.5 Hz, 1H), 5.44 (d, J = 18.5 Hz, 1H), 4.80 (d, J = 6.3 Hz,
2H), 4.60 (d, J = 8.7 Hz, 1H), 4.36 (s, 1H), 4.17 (s, 1H), 4.01 (s, 1H), 3.95 – 3.79 (m, 3H), 3,
3.70 (s, 6H), 3.60 (s, 3H), 3.47 (s, 3H), 3.08 (m, 3H), 3.03 (m, 3H), 2.86 (d, J = 7.1 Hz, 1H),
2.78 (s, 1H), 2.60-2.32 (m, 5H), 2.21 – 1.98 (m, 4H), 1.83 (m, 3H), 1.67 (t, J = 6.7 Hz, 3H),
1.56 (br. s, 4H) 1.31 (m, 2H). 13C NMR (MeOD, 101 MHz) δ 174.30, 173.45, 172.41,
171.99, 169.49, 169.40, 169.24, 143.12, 141.31, 138.38, 138.21, 136.42, 134.93, 134.49,
132.42, 130.83, 130.21, 128.13, 123.05, 121.13, 118.21, 115.30, 112.39, 109.05, 104.86,
99.38, 96.88, 53.87, 53.19, 51.07, 49.15, 48.73, 39.86, 39.15, 38.98, 37.50, 36.18, 35.26,
34.82, 30.76, 30.52, 29.83, 26.79, 22.43, 21.66, 18.72, 15.78, 11.06, 10.83, 9.62. MS
(MALDI-TOF) m/z 967.602 [M+H]+, calcd. for C50H67N10O10 967.504
Cell Studies
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All reagents used in these studies were purchased from Invitrogen. The human HEp2 cells
were obtained from ATCC and maintained in a 50:50 mixture of DMEM:AMEM
supplemented with 5% FBS and 1% penicillin/streptomycin antibiotic. The cells were subcultured twice weekly to maintain sub-confluent stocks.
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Time-Dependent Uptake—The HEp2 cells were plated at 7500 cells per well in a Costar
96-well plate and allowed to grow for 48 h. Compound stock solutions were prepared at 32
mM in DMSO and Cremophor (10% of Cremophor in DMSO). Further dilution into the
cells of the 96-well plate gave a final concentration of 400 μM with maximum DMSO
concentration of 1.95% and Cremophor concentration of 0.05%. Uptake was allowed to
continue for 0, 1, 2, 4, 8, 12 and 24 h. The uptake was terminated by removing the loading
medium and washing the wells once with PBS. The compound concentration was measured
using intrinsic fluorescence as measured with a BMG FLUOstar plate reader equipped with
a 355 nm excitation and a 650 nm emission filter. The cells were measured using a CyQuant
Cell proliferation assay as per manufacturer’s instructions.
Cytotoxicity—The HEp2 cells were plated as described above for the uptake experiment.
The compounds were diluted into media to give 400 μM solution concentrations. Two-fold
serial dilutions were then prepared and the cells were incubated overnight. Cell toxicity was
measured using Promega’s Cell Titer Blue viability assay47 as per manufacturer’s
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instructions, with untreated cells considered 100% viable and cells treated with 0.2%
saponin as 0% viable.
The cells were prepared as described above with compound concentration range from 0-100
μM. After loading overnight, the medium was replaced with medium containing 50 mM
HEPES pH 7.2. The cells were exposed to a 1000 W halogen lamp filtered through a 610 nm
liquid filter to provide approximately 1.5 J/cm2 light dose. The cells were kept cool by
filtering the IR radiation through 10 mm of water and placing the culture in an Echotherm
chilling plate (Torrey Pines Scientific, Inc.). After 20 min exposure to light, the plate was
incubated overnight. Cell viability was then measured as described above.
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In comparison with the previously investigated mono-amino acid derivatives of chlorin e6,27
the di-amino acid conjugates appear to be less phototoxic than the 131- and the 152-aspartate
derivatives (IC50 = 0.6 and 4.0 uM at 1 J/cm2), probably due to the higher hydrophilicity of
the di(amino acid) conjugates.
Microscopy—The Hep2 cells were plated in a 6-well plate and allowed to grow overnight.
The cells were exposed to 10 μM of each compound, and then kept at 37 °C for 6 h in 5%
CO2 before adding the organelle tracer. The working concentrations of organelle tracers
were as follows: LysoSensor Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/
white 100 nM, and BODIPY FL C5 Ceramide 50 nM. The organelle tracers were diluted in
growing medium and the cells were incubated concurrently with the compound and the
tracer for 30 min. The loading medium was removed and cells were washed with PBS 3
times before imaging. The images were acquired using a Leica DMRXA2 microscope with a
water immersion objective and DAPI, GFP, and TRITC filter cubes (Chroma Technologies).
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Conclusions
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Previous work27 has shown 131-monoconjugates of chlorin e6 to be more potent PDT
sensitizers (with regard to dark- and photo-toxicity) than the corresponding 152monoconjugates. In the present work a series of chlorin e6 di(amino acid) conjugates were
regioselectively synthesized bearing two aspartates in the 131,173- and 152,173-positions, or
at the 131,152 via an ethylene diamine linker. One conjugate bearing two different amino
acids, lysine at 131 via an ethylene diamine linker and an aspartate at 152 via a β-alanine
linker was also synthesized. The conjugation of aspartate residues via the α-amine groups
gave anionic compounds while conjugation via the carboxylate gave a zwitterionic
compound. The cytotoxicity and uptake of four di(amino acid) chlorin e6 conjugates, two
anionic and two zwitterionic, were investigated in human HEp2 cells, and compared with
chlorin e6. The most cytotoxic, IC50 (dark) = 65-70 μM and IC50 (light) = 9-11 μM, were the
zwitterionic 131,152-disubstituted conjugates 28 and 33; these were also the most taken up
by cells and localized in multiple organelles. On the other hand, the tetra-anionic 131,173and 152,173-di-aspartyl chlorin e6 12 and 13 showed low dark cytoxicity and lower
phototoxicity compared with chlorin e6. These di(amino acid) derivatives of chlorin e6
appear to be less phototoxic than previously investigated 131- and 152-mono aspartate
chlorin e6 derivatives,27 maybe due to their increased hydrophilicity.
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Figure 1.

All possible bis-amino acid regioisomers of chlorin e6
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Figure 2.

NMR spectral comparison of: A) methyl pheoporbide a (21); B) β-ketoamide 22
(*contains 10% of ring-opened product 24); and C) 131-ethylene-diaminyl-chlorin e6
dimethyl ester 24. Assignments: a, 132 CH; b, 133 CO2CH3; c, 151 CH2; d, 152 CO2CH3.
1H
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Figure 3.

Time-dependent uptake of chlorin e6 (1, green) and its derivatives 152,173-di(Asp)Ce6 MME
(12, blue), 131,173-di(Asp)Ce6 MME (13, red), 131,152-di(EDAsp)Ce6 MME (28, purple)
and 131-EDLys-152-β-AlaAspCe6 MME (33, black), at 10 μM by HEp2 cells.
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Figure 4.

Subcellular localization of 152,173-di(aspartate) chlorin e6 12 in HEp2 cells at 10 μM for 6h,
(a) phase contrast, (b) overlay of 12 and phase contrast, (c) ER Tracker Blue, (d) overlay of
12 and ER Tracker Blue, (e) BODIPY Ceramide, (f) overlay of 12 and BODIPY Ceramide,
(g) MitoTracker Green, (h) overlay of 12 and MitoTracker Green, (i) LysoSensor Green, (j)
overlay of 12 and LysoSensor Green. Scale bar: 10 μm.
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Figure 5.

Subcellular localization of 152,173-di(aspartate) chlorin e6 13 in HEp2 cells at 10 μM for 6h,
(a) phase contrast, (b) overlay of 13 and phase contrast, (c) ER Tracker Blue, (d) overlay of
13 and ER Tracker Blue, (e) BODIPY Ceramide, (f) overlay of 13 and BODIPY Ceramide,
(g) MitoTracker Green, (h) overlay of 13 and MitoTracker Green, (i) LysoSensor Green, (j)
overlay of 13 and LysoSensor Green. Scale bar: 10 μm.
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Figure 6.

Subcellular localization of 152,173-di(aspartate) chlorin e6 28 in HEp2 cells at 10 μM for 6h,
(a) phase contrast, (b) overlay of 28 and phase contrast, (c) ER Tracker Blue, (d) overlay of
28 and ER Tracker Blue, (e) BODIPY Ceramide, (f) overlay of 28 and BODIPY Ceramide,
(g) MitoTracker Green, (h) overlay of 28 and MitoTracker Green, (i) LysoSensor Green, (j)
overlay of 28 and LysoSensor Green. Scale bar: 10 μm.
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Figure 7.

Subcellular localization of 152,173-di(aspartate) chlorin e6 33 in HEp2 cells at 10 μM for 6h,
(a) phase contrast, (b) overlay of 33 and phase contrast, (c) ER Tracker Blue, (d) overlay of
33 and ER Tracker Blue, (e) BODIPY Ceramide, (f) overlay of 33 and BODIPY Ceramide,
(g) MitoTracker Green, (h) overlay of 33 and MitoTracker Green, (i) LysoSensor Green, (j)
overlay of 33 and LysoSensor Green. Scale bar: 10 μm.
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Scheme 1.

Proposed intermediates in the formation of 152,173 di-aspartic acid derivative 8.
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Scheme 2.

Synthesis of 152,173-diaspartylchlorin e6 methyl ester (12).(Reagents: i. 3 equiv. DCC,
DMAP, CH2Cl2, 2 h; ii. 3 equiv. Asp di-t-Bu.HCl, DIEA, rt, 24 h; iii. CH2N2, CH2Cl2, 5
min, 30% (3 steps); iv. TFA/CH2Cl2 (1:3), thioanisole, 6 h, rt, 88%.)
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Scheme 3.

Retrosynthetic route to 131,173-di(amino acid) derivatives, Method 1.
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Scheme 4.

Retrosynthetic route to 131,173-di(amino acid) derivatives, Method 2
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Scheme 5.

Synthesis of 131,173-diaspartyl chlorin e6 methyl ester (13). (Reagents: i. DCC, DMAP,
CH2Cl2, 1 h; ii. 0.5 M NaOMe/MeOH, 0 °C, 99% (2 steps); iii. HOBt, TBTU, DMF, L-Asp
di-t-Bu.HCl, DIEA, CH2Cl2, rt, 48 h, 48%; iv. TFA/CH2Cl2, thioanisole, 6 h, rt, 53%.).
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Scheme 6.

Attempted synthesis of 131,152-bis-ethylenediamine substituted chlorin e6 derivative 23
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Scheme 7.

Synthesis of 131,152-di(ethylenediaminylaspartyl)chlorin e6 28, (Reagents: i. 1.5 equiv
(Boc)NHCH2CH2NH2, toluene, 100 °C, 12-16 h, 65%; ii. 10 equiv NH2CH2CH2NH2,
toluene, 45 °C, 12 h, 64%; iii. TFA, CH2Cl2 1:3, 6 h, rt, 88%; iv. Boc-Asp(O-tBu)OH,
DIEA, CH2Cl2, TBTU, DMF, 40%; iv. TFA/CH2Cl2 1:3, 6 h, rt, 70%.)
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Scheme 8.

Synthesis of 131,152-di(amino acid) derivative 33. (Reagents: i. 1.5 equiv
NH2CH2CH2CO2t-Bu, toluene, 100 °C, 12-16 h, 54%; ii. TFA, CH2Cl2 1:3, 6 h, rt, 99%; iii.
L-Asp di-t-Bu.HCl, DIEA, CH2Cl2, HOBt, TBTU, DMF, 59%; iv. 10 equiv
NH2CH2CH2NH2, toluene, 45 °C, 12 h, 58%; v. Boc-Lys(Boc)-OH, DCHA, DIEA, CH2Cl2,
HOBt, TBTU, DMF; vi. TFA, CH2Cl2 1:3, 6 h, rt, 88%; iv. Boc-Asp(O-t-Bu)OH, DIEA,
CH2Cl2, TBTU, DMF, 40%; iv. TFA/CH2Cl2 1:3, 12 h, rt, 48% (2 steps).
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Dark and phototoxicity (~ 1.5 J/cm2) for chlorin e6 and its di-amino acid derivatives in HEp2 cells, using a
Cell Titer Blue assay
Compound

Dark toxicity
(IC50, μM)

Phototoxicity
(IC50, μM)

Ratio

Chlorin e6 (1)

350

14.5

24.1

152,173-di(Asp)Ce6 MME (12)

>400

35

>11

131,173-di(Asp)Ce6 MME (13)

305

26

11.7

131,152-di(EDAsp)Ce6 MME (28)

70

11

6.4

131-EDLys-152-β-AlaAspCe6
MME (33)

65

9.1

7.2
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Major and minor subcellular sites of localization for chlorin e6 and its di-amino acid derivatives in HEp2 cells
Compound

Lyso

ER

Golgi

Mito

Chlorin e6 (1)

+

++

−

−

152,173-di(Asp)Ce6 MME (12)

+

+

+++

−

131,173-di(Asp)Ce6 MME (13)

+++

+

+++

−

131,152-di(EDAsp)Ce6 MME (28)

+++

+

+++

−

131-EDLys-152-β-AlaAspCe6
MME (33)

+++

+

+++

+
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